Edition:
United Kingdom

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.29USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$2.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
281,455
52-wk High
$4.24
52-wk Low
$0.63

Latest Key Developments (Source: Significant Developments)

Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT.AVEO- UNDER MOU, AGREED FOR PLAINTIFFS TO CAUSE SOME OF CO'S, INDIVIDUAL DEFENDENTS' INSURANCE CARRIERS TO PROVIDE THE CLASS WITH $15 MILLION CASH PAYMENT.AVEO PHARMACEUTICALS SAYS ADDITIONALLY, CO AGREED TO ISSUE TO THE CLASS WARRANTS FOR PURCHASE OF 2 MILLION SHARES OF AVEO COMMON STOCK - SEC FILING.AVEO PHARMACEUTICALS - IN CONSIDERATION OF SETTLEMENT PAYMENT, PLAINTIFFS AGREED THAT SETTLEMENT WILL INCLUDE DISMISSAL OF CLASS ACTION WITH PREJUDICE.AVEO PHARMA - CONSIDERING SETTLEMENT PAYMENT, PLAINTIFFS AGREED SETTLEMENT WILL INCLUDE RELEASE OF ALL CLAIMS AGAINST CO, INDIVIDUAL DEFENDANTS BY THE CLASS.  Full Article

Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Aveo Pharmaceuticals Inc :AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.22.‍BELIEVE THAT OUR $37.4 MILLION IN CASH RESOURCES WOULD ALLOW US TO FUND OUR PLANNED OPERATIONS INTO Q4 OF 2018​.  Full Article

Aveo Pharmaceuticals files for non-timely 10-K - SEC filing
Friday, 17 Mar 2017 

Aveo Pharmaceuticals Inc : Files for non-timely 10-K - SEC filing . Says identified a material weakness in its internal control over financial reporting. . Aveo Pharmaceuticals - based on preliminary figures, expects to report net loss of $0.39 per basic and diluted share, for year ended December 31, 2016 .Aveo Pharmaceuticals - material weakness related to company's failure during 2016 to regularly reconcile U.K. bank account held by co's U.K. subsidiary.  Full Article

Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma
Monday, 15 Aug 2016 

Aveo : Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo® (nivolumab) in advanced renal cell carcinoma .Phase 1/2 tinivo trial to commence at institut gustave roussy in paris.  Full Article

Aveo Oncology Q2 loss per share $0.13
Thursday, 4 Aug 2016 

Aveo Pharmaceuticals Inc : Aveo oncology reports second quarter 2016 financial results and provides business update . Q2 loss per share $0.13 Further company coverage: [AVEO.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Aveo Reports Q1 Loss Per Share $0.08

* AVEO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE